CheckMate 227: nivolumab plus ipilimumab gives higher 7-year survival than chemotherapy in NSCLC
Final 7.5-year results show 7-year overall survival of 19% versus 10% in PD-L1-positive disease, and 14% versus 4% in PD-L1-negative disease, Stephen V Liu reported.
“In PD-L1+, 7y OS 19% with nivo/ipi vs 10% with chemo with rates of ongoing response 25% vs 3%.”— Stephen V Liu, MD
Final 7.5-year outcomes from the CheckMate 227 trial of first-line nivolumab plus ipilimumab in non-small cell lung cancer (NSCLC) have been published in JTO, according to a post on X by thoracic oncologist Stephen V Liu.
In patients with PD-L1-positive disease, Liu wrote, 7-year overall survival (OS) was 19% with nivolumab and ipilimumab, compared with 10% with chemotherapy. Rates of ongoing response were 25% with the immunotherapy combination versus 3% with chemotherapy.
In PD-L1-negative disease, 7-year OS was 14% with nivolumab and ipilimumab versus 4% with chemotherapy. Ongoing responses were reported in 20% of patients on the combination versus 3% on chemotherapy.
Liu is Chief of Hematology and Oncology at Georgetown and MedStar Georgetown University Hospital, according to his profile.
Original source
“In PD-L1+, 7y OS 19% with nivo/ipi vs 10% with chemo with rates of ongoing response 25% vs 3%.”
— Stephen V Liu, MD View the post on X